Genelux (GNLX) Non Operating Investment Income (2024 - 2026)
Genelux (GNLX) posted quarterly Non Operating Investment Income of -$14000.0 for Q1 2026, up 60.0% year-over-year from -$8750.0 in Q1 2025, and down 1500.0% quarter-over-quarter from $1000.0 in Q4 2025.
Genelux (GNLX) Non Operating Investment Income (2024 - 2026) Analysis & Trends
Genelux's Non Operating Investment Income history runs 3 years deep, the most recent figure standing at -$14000.0 for Q1 2026.
- In Q1 2026, Non Operating Investment Income rose 60.0% year-over-year to -$14000.0; the TTM figure through Mar 2026 stood at -$34000.0 (down 200.0% YoY), while the FY2025 annual figure was -$55000.0, down 210.0% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at -$14000.0, down from $1000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $135000.0 in Q3 2024, with the low at -$60000.0 in Q4 2024.
- The 3-year median for Non Operating Investment Income is -$14000.0 (2026), against an average of -$2111.1.
- Peak annual rise in Non Operating Investment Income reached 101.67% in 2025, while the deepest fall reached 333.33% in 2025.
- Genelux's Non Operating Investment Income stood at -$60000.0 in 2024, then jumped by 101.67% to $1000.0 in 2025, then slumped by 1500.0% to -$14000.0 in 2026.
- Business Quant data shows GNLX's Non Operating Investment Income at -$14000.0 in Q1 2026, $1000.0 in Q4 2025, and $5000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Genelux | 120.53 Mn | 120.53 Mn | - | -14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,000.00 |
| Mar 31, 2026 | -14,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | -26,000.00 |
| Jun 30, 2025 | -26,000.00 |
| Mar 31, 2025 | -35,000.00 |
| Mar 31, 2025 | -35,000.00 |
| Dec 31, 2024 | -60,000.00 |
| Dec 31, 2024 | -60,000.00 |
| Sep 30, 2024 | 135,000.00 |
| Sep 30, 2024 | 135,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Mar 31, 2024 | -19,000.00 |